• The only company from pharmaceutical industry selected for inclusion in the Index
• Also included in HSI ESG Index and Hang Seng ESG 50 Index
• Green CRDMO solution provider with outstanding sustainability performance

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced its inclusion in the 2025 Hang Seng Corporate Sustainability Benchmark Index. It stands out as the only company from the pharmaceutical industry selected for this prestigious recognition. The company has also been previously honored for its inclusion in both the HSI ESG Index and the Hang Seng ESG 50 Index.

The Hang Seng Corporate Sustainability Benchmark Index recognizes publicly listed companies that demonstrate outstanding ESG performance, providing benchmarks for sustainability investments. Constituent selection follows a comprehensive process based on the results from a sustainability assessment undertaken annually by the Hong Kong Quality Assurance Agency (HKQAA), an independent and professional assessment body, using its proprietary sustainability assessment and rating framework.

As a global provider of biologics Green CRDMO solutions, WuXi Biologics has consistently embraced sustainability principles as integral to its robust business growth — advancing sustainable practices in biologics green research, development, manufacturing, and operations; optimizing energy and resource efficiency; enhancing governance transparency; and demonstrating unwavering dedication to employee welfare and societal improvement.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "Being included in the Hang Seng Indexes is a significant recognition of our continuous efforts in pursuing sustainability. As a global leader in Green CRDMO, we will remain committed to creating long-term value for stakeholders while contributing to society and the environment."

In line with the United Nations Sustainable Development Goals, WuXi Biologics has been actively engaged with the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI). The company's new near-term and net-zero greenhouse gas emissions-reduction target matrix has been approved by the Science Based Targets initiative (SBTi) in August.

Over the past few years, WuXi Biologics has earned widespread recognition for its dedicated efforts in sustainability. The company was granted MSCI AAA ESG Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.